Ozempic vs Retatrutide: Eli Lilly claims 'more than double' the weight loss in latest trial — What's next?

Mint - Oct 29, 2026

Retatrutide is widely expected to fuel Lilly's next wave of growth following the success of its Zepbound and Mounjaro.

Read full article

MORE NEWS

Science Thread

Science Thread delivers quality and fascinating science and technology content that matters on a daily basis and makes it go viral.

Sign Up